BridgeBio provided updates on its commercial progress for Attruby (acoramidis), late-stage pipeline programs, and anticipated 2026 milestones at the 44th Annual J.P. Morgan Healthcare Conference.
Attruby recorded preliminary unaudited net product revenue of $146.0 million in Q4 and $362.4 million for the full year 2025.
Attruby is showing strong adoption with 6,629 unique patient prescriptions written by 1,632 prescribers by December 31, 2025.
Attruby Revenue
Preliminary unaudited Q4 and Full Year 2025 net revenue: $146.0 million and $362.4 million, respectively.
ATTR-CM Therapy
Attruby becoming first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions.
Pipeline Programs
New programs announced, such as TTR amyloid depleter antibody program, with expected advances into clinic between 2027-2028.
- BridgeBio's Phase 3 study of LGMD2I/R9 showed broad benefits and a significant 2.6 point improvement on NSAD relative to placebo at 12 months, leading to FDA recommendation for NDA submission.
- The company plans to submit an NDA for the results of the CALIBRATE Phase 3 trial in the first half of 2026, showcasing rapid progress in research and development.
BridgeBio's strong financial position, with approximately $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025, positions it well to sustain the acceleration of Attruby and potentially launch three additional medicines globally.